Allergan buys chin fat firm Kythera for $2.1bn
This article was originally published in Scrip
Executive Summary
Allergan is now geared up to treat all signs of facial aging, it claims. The Irish-headquartered firm is to buy Kythera Biopharmaceuticals and its approved submental fullness (double chin) drug Kybella (ATX-101) for $75 per Kythera share, or around $2.1bn. The drug, which has a US launch slated for the third quarter of this year, will slot neatly into Allergan's facial aesthetics portfolio, which includes Botox, and serve as a "pivotal entry point for expanding the use of facial aesthetic products in men," hopes Allergan.
You may also be interested in...
Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain
Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.
Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs
Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.